Latest Conference Articles

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the significance of the TAPUR clinical trial, which is being conducted by ASCO.

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the CheckMate-141 trial, which found that treatment with single-agent nivolumab (Opdivo) reduced the risk of death by 30% and doubled 1-year overall survival (OS) rates compared with investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN).

Maura N. Dickler, MD, Memorial Sloan Kettering Cancer Center, discusses the results of the single-arm MONARCH 1 trial, which examined the efficacy of the CDK4/6 inhibitor abemaciclib in heavily pretreated patients with refractory, hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.

Reinhard Dummer, MD, professor, Department of Dermatology, University of Zurich Hospital, discusses the results of the phase III NEMO trial, which compared the efficacy of binimetinib with dacarbazine in patients with NRAS-mutant metastatic melanoma.

David A. Reardon, MD, discusses results of a cohort from the open-label CheckMate-143 trial, which explored the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with recurrent glioblastoma multiforme (GBM).

Bernard A. Fox, PhD, chief, Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute at Providence Portland Medical Center, discusses the significance of the Immunoscore Validation Project.

Arjun V. Balar, MD, assistant professor, Department of Medicine, co-leader of the Genitourinary Cancers Program, discusses updated results of cohort 1 of the IMvigor 210 study, which examined the efficacy of atezolizumab as first-line therapy in patients with cisplatin-ineligible locally advanced/metastatic urothelial carcinoma.

Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the phase III results of the CASTOR trial, which was a randomized controlled study examining the efficacy of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

John D. Hainsworth, MD, co-founder; principal investigator, Sarah Cannon Research Institute, discusses the results of the MyPathway trial, which was an open-label, phase IIa umbrella basket study.

Michele Cavo, MD, professor, Seràgnoli Institute of Hematology Bologna University School of Medicine, discusses the results of the phase III EMN02/HO95 MM trial, which compared the efficacy of upfront autologous stem cell transplantation versus novel agent-based therapy for the treatment of patients with multiple myeloma.

Andreas Hochhaus, MD, professor of Internal Medicine, Hematology and Oncology, interim head of the Department of Hematology and Medical Oncology, University Medical Center Jena in Germany, discusses results of the phase II ENESTFreedom study, which examined treatment-free survival (TFS) in patients with chronic myeloid leukemia (CML) who received frontline nilotinib (Tasigna).

Hossein Borghaei, DO, chief, Thoracic Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses 2-year follow-up results of the CheckMate-017 and -057 studies, which compared the efficacy of nivolumab (Opdivo) versus docetaxel in patients with advanced non–small cell lung cancer (NSCLC).

Krishna Vanaja Donkena, PhD, Assistant Professor of Biochemistry and Molecular Biology, Center for Individualized Medicine, Mayo Clinic, discusses using immune and checkpoint markers to predict cancer-specific survival in bladder cancer.

Dennise Geiger, RN, Regional Cancer Care Associates, Central Jersey Division, discusses difficulties nurses face when using telephone triage, and the plan that was developed to better streamline the process. 

Kathryn Ciccolini, RN, BSN, OCN, DNC, Memorial Sloan Kettering Cancer Center, discusses the concept she developed to manage dermatologic adverse events for patients with cancer.

Ellyn Matthews, PhD, RN, AOCNS, CBSM, who holds the Elizabeth Stanley Cooper Endowed Chair in Oncology Nursing at the University of Arkansas for Medical Sciences, addresses common misconceptions that patients with cancer have about sleep disturbances.

Jeannine Brant, PhD, Billings Clinic, discusses the benefits of patient-reported outcomes in cancer care.

Carmela Hoefling, RN, MSN, APN-C, AOCNP, advanced practice nurse, Gastrointestinal/Hepatobiliary Oncology Program, Rutgers Cancer Institute of New Jersey, discusses the effects that malnourishment can have on surgery.

Joel Stettler, BSN, RN, OCN, Moffitt Cancer Center, discusses procedures implemented at his institution for patients who are at risk for falls. 

Darcy Burbage, RN, MSN, AOCN, CBCN, Helen F. Graham Cancer Center & Research Institute, discusses the role nurses play in treating patients with chemotherapy-induced peripheral neuropathy (CIPN).

David Eagle, MD, past president of the Community Oncology Alliance (COA) and partner in Lake Norman Oncology, Mooresville, North Carolina, discuss controlling costs of cancer treatment.

Jeff Geschwind, MD, professor and chairman, Radiology and Biomedical Imaging, Yale Cancer Center, discusses locoregional treatment options for patients with hepatocellular carcinoma (HCC).

Douglas B. Evans, MD, FACS, Chair, Professor, Donald C. Ausman Family Foundation Professor of Surgery, Medical College of Wisconsin, discusses how to appropriately sequence therapies for pancreatic cancer.

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses about 2 agents, regorafenib and TAS-102, for the treatment of patients with treat colorectal cancer.

Dr. Christopher Heery, medical oncologist, National Cancer Institute, discusses the progress that has been made in the treatment of patients with neuroendocrine tumors.

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the CheckMate-141 trial, which found that treatment with single-agent nivolumab (Opdivo) reduced the risk of death by 30% and doubled 1-year overall survival (OS) rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN).

Samir N. Khleif, MD, director, GRU Cancer Center, discusses next steps researchers and physicians need to take with immunotherapy in the field of oncology.

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses a study demonstrating the benefit of utilization of the Cologuard screening test for colorectal cancer (CRC).

Angela M. DeMichele, MD, professor of Medicine and Epidemiology, University of Pennsylvania, discusses results of the HER2-positive breast cancer cohort of the phase II ISPY-2 trial, which investigated the neoadjuvant combinations of ado-trastuzumab emtansine (T-DM1) and pertuzumab (Perjeta) versus paclitaxel (Abraxane) and trastuzumab (Herceptin).